MYO240517C2500
- 1.12
- -0.63-36.00%
Myomo Newsroom
Insider Sale: Chief Medical Officer Harry Kovelman Sells 35,426 Shares of Myomo Inc (MYO)
Myomo(MYO.US) Officer Sells US$130.84K in Common Stock
$Myomo(MYO.US)$ Officer Kovelman Harry sold 35,426 shares of common stock on May 15, 2024 at an average price of $3.6933 for a total value of $130.84K.Source: Announcement What is statement of changes
Express News | Myomo Inc : Ascendiant Capital Markets Raises Target Price to $8.25 From $8
Form 144 | Myomo(MYO.US) Officer Proposes to Sell 130.84K in Common Stocks
SEC FILLINGS DISCLOSED/ May 15, $Myomo(MYO.US)$ Officer HARRY KOVELMAN intends to sell 35,426 shares of its common stock on May 15, with a total market value of approximately $130.84K. HARRY KOVELMA
Myomo Inc Reports Q1 2024 Earnings: Revenue Up Despite Challenges
Myomo's Strategic Turnaround: A Buy Rating With Revenue Growth and Operational Scaling on the Horizon
Earnings Call Summary | Myomo(MYO.US) Q1 2024 Earnings Conference
The following is a summary of the Myomo, Inc. (MYO) Q1 2024 Earnings Call Transcript:Financial Performance:Myomo reported Q1 2024 revenue of $3.8 million, up 9% over Q1 of previous year, driven by a h
Express News | HC Wainwright & Co. Reiterates Buy on Myomo, Maintains $6.5 Price Target
Myomo Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 78.08% HC Wainwright & Co. → $6.5 Reiterates Buy → Buy 12/15/2023 78.08% HC Wainwright & Co. →
Express News | Myomo Inc : Alliance Global Partners Raises Target Price to $5.25 From $4.75
Myomo's Strong Growth Potential Amid New CMS Guidelines Elicits a Buy Rating
Myomo Says Given Our Backlog, We're In A Position To Generate More Than $5M In Product Revenue In Q2 Vs $5.12M Est; Says Have The Opportunity To Generate Between $28M-$30M In Revenue In FY24 Vs 26.67M Est.
Business Outlook"Given our backlog, we're in a position to generate more than $5.0 million in product revenue in the second quarter," added Mr. Gudonis. "We're making progress on our capacity expansio
Myomo Q1 2024 GAAP EPS $(0.10), Inline, Sales $3.754M Miss $4.071M Estimate
Myomo (AMEX:MYO) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last yea
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersCytomX Therapeutics (NASDAQ:CTMX) stock increased by 87.1% to $7.84 during Wednesday's after-market session. The market value of their outstanding shares is at $534.1 million. As per the press
Myomo | 10-Q: Quarterly report
Press Release: Myomo Reports First Quarter 2024 Financial Results
Myomo Reports First Quarter 2024 Financial Results Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the
Express News | Myomo Q1 Operating Expenses USD 6.2 Million
Express News | Myomo Q1 Operating Income USD -3.9 Million
Myomo 1Q Loss/Shr 10c >MYO
Myomo 1Q Loss/Shr 10c >MYO
Myomo Receives Reimbursements For MyoPros From CMS
Myomo (MYO) said Monday that the Centers for Medicare & Medicaid Services have paid lump sum reimbursements to the company through their regional contractors. The company said they are beginning to re